VBI Historical Income Statement
| VBIV Stock | USD 0.60 0.01 1.69% |
Historical analysis of VBI Vaccines income statement accounts such as Interest Expense of 8.5 M, Selling General Administrative of 44.3 M, Total Revenue of 9.1 M or Other Operating Expenses of 67.2 M can show how well VBI Vaccines performed in making a profits. Evaluating VBI Vaccines income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of VBI Vaccines's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining VBI Vaccines latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether VBI Vaccines is a good buy for the upcoming year.
VBI |
About VBI Income Statement Analysis
VBI Vaccines Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to VBI Vaccines shareholders. The income statement also shows VBI investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
VBI Vaccines Income Statement Chart
VBI Vaccines Income Statement is one of the three primary financial statements used for reporting VBI's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of VBI Vaccines revenue and expense. VBI Vaccines Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, VBI Vaccines' Research Development is fairly stable compared to the past year. Interest Income is likely to climb to about 2.1 M in 2024, despite the fact that Operating Income is likely to grow to (52.5 M). Add Fundamental
Total Revenue
Total revenue comprises all receipts VBI Vaccines generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of VBI Vaccines. It is also known as VBI Vaccines overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from VBI Vaccines' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into VBI Vaccines current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VBI Vaccines. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.At this time, VBI Vaccines' Research Development is fairly stable compared to the past year. Interest Income is likely to climb to about 2.1 M in 2024, despite the fact that Operating Income is likely to grow to (52.5 M).
| 2023 | 2024 (projected) | Non Recurring | 5.7M | 5.0M | Reconciled Depreciation | 2.0M | 1.6M |
VBI Vaccines income statement Correlations
Click cells to compare fundamentals
VBI Vaccines Account Relationship Matchups
High Positive Relationship
High Negative Relationship
VBI Vaccines income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 2.2M | 2.7M | 4.7M | 4.0M | 8.1M | 8.5M | |
| Selling General Administrative | 14.1M | 20.7M | 38.3M | 56.1M | 42.1M | 44.3M | |
| Total Revenue | 2.2M | 1.1M | 631K | 1.1M | 8.7M | 9.1M | |
| Gross Profit | (5.7M) | (8.1M) | (10.1M) | (10.2M) | (5.8M) | (5.5M) | |
| Other Operating Expenses | 48.3M | 44.7M | 68.7M | 82.9M | 64.0M | 67.2M | |
| Operating Income | (52.4M) | (43.6M) | (68.0M) | (81.8M) | (55.3M) | (52.5M) | |
| Ebit | (52.4M) | (43.6M) | (68.0M) | (81.8M) | (55.3M) | (52.5M) | |
| Ebitda | (46.1M) | (42.0M) | (66.2M) | (79.8M) | (53.3M) | (50.7M) | |
| Total Operating Expenses | 40.4M | 35.5M | 57.9M | 71.6M | 49.5M | 52.0M | |
| Income Before Tax | (54.8M) | (46.2M) | (69.8M) | (113.3M) | (92.8M) | (88.2M) | |
| Total Other Income Expense Net | (2.4M) | (2.6M) | (1.7M) | (31.5M) | (37.5M) | (35.6M) | |
| Net Income | (55.8M) | (47.3M) | (72.7M) | (141.0M) | (92.8M) | (88.2M) | |
| Income Tax Expense | 992K | 1.1M | 2.9M | 27.6M | 31.8M | 33.4M | |
| Depreciation And Amortization | 6.3M | 1.7M | 1.8M | 2.1M | 2.0M | 2.1M | |
| Cost Of Revenue | 7.9M | 9.2M | 10.8M | 11.3M | 14.5M | 15.2M | |
| Net Income From Continuing Ops | (54.8M) | (46.2M) | (69.8M) | (113.3M) | (114.0M) | (108.3M) | |
| Research Development | 26.3M | 14.9M | 19.6M | 15.5M | 9.3M | 15.8M | |
| Net Income Applicable To Common Shares | (54.8M) | (46.2M) | (69.8M) | (113.3M) | (102.0M) | (96.9M) | |
| Interest Income | 835K | 613K | 372K | 1.4M | 2.0M | 2.1M | |
| Net Interest Income | (2.2M) | (2.7M) | (4.7M) | (3.8M) | (5.9M) | (5.6M) | |
| Non Operating Income Net Other | (218K) | 95K | 3.0M | (27.5M) | (24.7M) | (23.5M) | |
| Reconciled Depreciation | 1.2M | 1.7M | 1.8M | 2.1M | 2.0M | 1.6M |
Pair Trading with VBI Vaccines
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if VBI Vaccines position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in VBI Vaccines will appreciate offsetting losses from the drop in the long position's value.Moving against VBI Stock
| 0.42 | VERA | Vera Therapeutics | PairCorr |
The ability to find closely correlated positions to VBI Vaccines could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace VBI Vaccines when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back VBI Vaccines - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling VBI Vaccines to buy it.
The correlation of VBI Vaccines is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as VBI Vaccines moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if VBI Vaccines moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for VBI Vaccines can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VBI Vaccines. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for VBI Stock analysis
When running VBI Vaccines' price analysis, check to measure VBI Vaccines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VBI Vaccines is operating at the current time. Most of VBI Vaccines' value examination focuses on studying past and present price action to predict the probability of VBI Vaccines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VBI Vaccines' price. Additionally, you may evaluate how the addition of VBI Vaccines to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |
Is VBI Vaccines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VBI Vaccines. If investors know VBI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VBI Vaccines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.49) | Revenue Per Share 0.481 | Quarterly Revenue Growth 1.503 | Return On Assets (0.29) | Return On Equity (4.20) |
The market value of VBI Vaccines is measured differently than its book value, which is the value of VBI that is recorded on the company's balance sheet. Investors also form their own opinion of VBI Vaccines' value that differs from its market value or its book value, called intrinsic value, which is VBI Vaccines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VBI Vaccines' market value can be influenced by many factors that don't directly affect VBI Vaccines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VBI Vaccines' value and its price as these two are different measures arrived at by different means. Investors typically determine if VBI Vaccines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VBI Vaccines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.